UCLA researchers from the Department of Medicine have developed a novel immunoassay for human erythroferrone.
Erythroferrone (ERFE) is a hormone that is secreted by developing red blood cells to increase iron absorption and availability, as iron is an essential component of hemoglobin. ERFE is secreted in response to the hormone erythropoietin. ERFE levels have been previously demonstrated in mouse studies to increase after hemorrhage or erythropoietin therapy analogous to athlete doping. In human studies, ERFE is increased after blood donation and erythropoietin therapy, in other conditions where erythropoiesis is stimulated such as polycythemia, and is dramatically increased in ineffective erythropoiesis, such as in β-thalassemia. However, until now there has not been a validated assay for human ERFE.
UCLA researchers have developed a quantitative immunoassay for human erythroferrone (ERFE) that has been validated in human patients. The working range that the immunoassay can detect is 14-100 ng/ml, which enables clinical measurements of physiological and pathological ERFE levels from standard blood sample.
|European Patent Office||Published Application||2017-787|
|Patent Cooperation Treaty||Reference for National Filings||WO2018226441||12/13/2018||2017-787|
Additional Patent Pending
erythroferrone, immunoassay, assay, erythropoietin, blood iron, thalassemia, anemia, polycythemia, athlete doping